The Wegovy tablet market is still moving quickly, but the pattern is becoming clearer. More UK providers are now showing live tablet prices, while others are still using listed or launch wording. That means the real job is not just finding a price, but separating live rows from launch pages and bundle offers.
What changed this week
The biggest shift is that the market now has enough live tablet coverage to compare like-for-like monthly pricing across a meaningful set of providers. That makes the baseline price table more useful, but it also means readers need to watch for provider pages that mix standard pricing with subscription, bundle or introductory offers.
What we are seeing on provider pages
- some providers are publishing dose-specific live prices
- some are still marking the tablet as being monitored or listed only
- some are adding discount-code or first-month offers beside the standard price
- a few pages still need careful checking because the tablet and injection routes are easy to mix up
Why it matters
For readers, the important difference is between a real public price and a launch page that looks like a price. For comparison work, the important difference is whether the provider has a clear dose ladder, a live availability status and a page that explains what the price actually includes.
What we will keep tracking
We will keep watching the live tablet prices, the launch radar, discount codes and the provider pages that appear to move first. We will also keep checking whether new pages are appearing for the Wegovy pill in places that previously only showed injections or older oral semaglutide products.
Read next
Start with the live price comparison, then check the provider directory if you want the support and delivery side as well.
